U.S.-listed shares of Novartis closed down 0.5% at $90.82.
Amgen is also suing Samsung Bioepis over its Enbrel biosimilar. That litigation remains under way, an Amgen spokeswoman said on Friday. Officials at Samsung Bioepis did not immediately respond to a request for comment.
(Reporting by Deena Beasley in Los Angeles Additional reporting by Jan Wolfe and Ankur Banerjee; editing by Shinjini Ganguli and Leslie Adler)